Advertisement

Monoamine oxidase inhibition by moclobemide and 2-Aminoethyl carboxamide derivatives: mode of action and kinetic characteristics

  • A. M. Cesura
  • D. Muggli-Maniglio
  • G. Lang
  • R. Imhof
  • M. Da Prada
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 32)

Summary

The selective, reversible inhibitors of monoamine oxidase (MAO) moclobemide and Ro 41-1049 (selective for MAO-A), as well as of Ro 16-6491 and Ro 19-6327 (selective for MAO-B) inhibited the enzyme with an initial competitive phase, followed by a time-dependent inhibition of MAO. Ro 41-1049, Ro 16-6491 and Ro 19-6327, being activated by MAO into reversible adducts, fit into the classification as mechanism-based inhibitors. Conversely, since no product formation was observed after incubation of tissue homogenates with moclobemide, this drug probably belongs to the class of the “slow-binding” MAO inhibitors.

Keywords

Monoamine Oxidase Human Platelet Carboxamide Derivative Deuterated Derivative Human Platelet Membrane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bach AWJ, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan S-W, Seeburg PH, Shih JC (1988) cDNA cloning of human liver monoamine oxidase A and B: molecular basis of difference in enzymatic properties. Proc Natl Acad Sci USA 85:4934–4938.PubMedCrossRefGoogle Scholar
  2. Cesura AM, Galva MD, Imhof R, Kyburz E, Picotti GB, Da Prada M (1989) [3H]Ro 19-6327: a reversible ligand and affinity labeling probe for monoamine oxidase-B. Eur J Pharmacol 162:457–465.PubMedCrossRefGoogle Scholar
  3. Cesura AM, Imhof R, Muggli-Maniglio D, Picotti GB, Da Prada M (1990a) Characterization of [3H]Ro 16-6491 binding to digitonin solubilized monoamine oxidase-B and purification of the enzyme from human platelets by affinity chromatography. Biochem Pharmacol 39:216–220.PubMedCrossRefGoogle Scholar
  4. Cesura AM, Bös M, Galva MD, Imhof R, Da Prada M (1990b) Characterization of the binding of [3H]Ro 41-1049 to the active site of human monoamine oxidase-A. Mol Pharmacol 37:358–366.PubMedGoogle Scholar
  5. Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Saura Marti J, Muggli-Maniglio D, Wyss P-C, Kyburz E, Imhof R (1990) From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm [Suppl] 29:279–292.Google Scholar
  6. Dostert PL, Strolin-Benedetti M, Tipton KF (1989) Interactions of monoamine oxidase with substrates and inhibitors. Med Res Rev 9:45–89.PubMedCrossRefGoogle Scholar
  7. Fowler CJ, Ross SB (1984) Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological, and clinical properties. Med Res Rev 4:323–358.PubMedCrossRefGoogle Scholar
  8. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285–1297.PubMedCrossRefGoogle Scholar
  9. Keller HH, Kettler R, Keller G, Da Prada M (1987) Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491. Naunyn-Schmiedebergs Arch Pharmacol 335:12–20.PubMedCrossRefGoogle Scholar
  10. Palfreyman MG, Bey P, Sjoerdsma A (1987) Enzyme-activated/mechanism-based inhibitors. Essays in Biochemistry 23:28–81.PubMedGoogle Scholar
  11. Tertrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245:519–522.CrossRefGoogle Scholar
  12. Williams JW, Morrison JF (1979) The kinetic of reversible tight-binding inhibition. Meth Enzymol 63:337–467.Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • A. M. Cesura
    • 1
  • D. Muggli-Maniglio
    • 1
  • G. Lang
    • 1
  • R. Imhof
    • 1
  • M. Da Prada
    • 1
  1. 1.Pharmaceutical Research DepartmentF. Hoffmann-La Roche LtdBaselSwitzerland

Personalised recommendations